-+ 0.00%
-+ 0.00%
-+ 0.00%

Molecular Partners publishes Phase 1 MP0317 data showing tumor-localized CD40 activation

PUBT·05/01/2026 11:00:27
Listen to the news
Molecular Partners publishes Phase 1 MP0317 data showing tumor-localized CD40 activation
  • Molecular Partners published Phase 1 monotherapy data for MP0317 in Nature Cancer, supporting tumor-localized CD40 activation in advanced solid tumors.
  • Results were previously presented at ASCO 2024, then at SITC 2024.
  • Study readout showed favorable safety profile, with signals of disease control in a heavily pretreated population.
  • Company highlighted pharmacokinetics that support combination use, including with checkpoint inhibitors.
  • Patient dosing is ongoing in an investigator-initiated randomized Phase 2 trial in front-line cholangiocarcinoma comparing MP0317 added to standard of care versus standard of care alone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605010700OMX_____CNEWS_EN_GNW9711214_en) on May 01, 2026, and is solely responsible for the information contained therein.